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ABSTRACT
APPROACHES IN THE TREATMENT OF PARKINSON'S DISEASE: A FOCUS ON
STEM CELL-BASED THERAPIES
Tareq Al-maqtari
March 1,2012
Parkinson's disease (PD) is a hypokinetic movement disorder resulting from the
progressive neurodegeneration of the dopaminergic nigrostriatal system in the brain and
the resulting imbalance between dopamine and acetylcholine in the basal ganglia motor
circuitry. Although drug-based therapy approaches have shown dramatic symptomatic
improvement in patients, they do not halt the progressive nature of the disease and their
long-term use is associated with distressing adverse side effects. Consequently, several
studies have aimed at discovering effective non-pharmacological strategies to reduce or
to eliminate the need for drugs and possibly to halt or to reverse the neurodegenerative
process in PD. Surgical deep brain stimulation, neurotrophic factor delivery, gene therapy
and cell replacement therapy are potential candidates. Here, we review the latest
advancements in the aforementioned therapeutic strategies paying special attention to
regenerative stem cell- (SC)-based approaches in combating PD. Although intracerebrally transplanted SC-derived cells can replace degenerated neurons in PD and
simultaneously secrete neurotrophic factors that can partly protect the viable ones,
potential tumorigenicity and low survivability of these cells hinder the advancement of
this novel therapeutic approach. Hence, more investigations are needed to resolve the
associated safety and efficacy concerns in order to make SC-based therapy a feasible
therapy for PD patients.
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CHAPTER I
INTRODUCTION
Parkinson's Disease
Parkinson's disease (PD) is a progressive degenerative disorder of the central nervous
system that primarily affects the elderly. It is named after the English· doctor, James
Parkinson, who first described the disease in 1817. PD affects around 18 per 100,000
person-years and has a higher prevalence in males (Corti et aI., 2011). The degenerative
symptoms of PD arise primarily from the progressive loss of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) of the midbrain (see figure 1) and result in motor
system abnormalities such as bradykinesia, tremors, muscular rigidity and postural
instability (Halliday and McCann, 2010).

PD-related symptoms progress in a time-dependent manner such that the presymptomatic stages are associated with smell and autonomic dysfunctions, the
symptomatic stages with motor abnormalities, and the final stages with dementia in many
cases. The slow progression of the disease results from neurodegeneration afflicting the
olfactory bulb and the medulla oblongata in pre-symptomatic stages 1 and 2, the SNpc in
stages 3 and 4, and the telencephalic cortex in stages 5 and 6 (Braak et aI., 2002). The
fact that PD patients also experience non-motor psychiatric, cognitive and autonomic
symptoms indicates that non-dopaminergic neurons also become affected in the course of
the disease (Chaudhuri et aI., 2006).
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Figure 1. Dopaminergic neurons or the suhstantia nigra compacta (SNc), which extend to the striatum ..
degenerate in Parkinson's disease . (Source of the piClUn.:: Longo DL, Fauci AS, Kasper DL. Hauser SL.
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Protein Aggregation and PD pathophysiology

Although the exact cause of PD remams largely unknown; inflammation, oxidative
stress, mitochondrial damage, dysfunction of the ubiquitin proteosome degradation
system, and altered activity of certain kinases, all appear to promote the formation of
Lewy

bodies,

intracellular

proteinaceous

aggregates

observed

m

PD-affected

dopaminergic neurons, eventually resulting in neuronal cell death (McNaught et aI. ,
2003; Schulz, 2008). The components of Lewy bodies include alpha-synuclein (SNCA)the major fibrillary component of these bodies, neurofilament proteins and ubiquitin
(Corti et aI., 2011). SNCA is abundantly expressed in the brain especially at presynaptic
2

nerve terminals where it may modulate dopaminergic transmission (Li et aI., 2004).
Mutations in SNCA increase the tendency of the corresponding protein to aggregate into
Lewy bodies, resulting in neuronal cell death (Goedert et aI., 1998). Whereas the exact
mechanistic relationship between Lewy bodies and cell death remains obscure, there is
some evidence that SNCA oligomers, not the fibrillary form, are responsible for neuronal
cell death (Goldberg and Lansbury, 2000), suggesting a possible detoxification role for
the Lewy bodies. These conclusions are supported by observations that Lewy bodies exist
in the surviving neurons of PD patients as well as in the neurons of healthy individuals
(Parkkinen et aI., 2005). Further, some studies postulate that dopamine plays a role in
stabilizing SNCA oligomers; promoting the selective degeneration of dopaminergic
neurons (Lansbury et aI., 2001). Although the exact role of SNCA in PD remains largely
unknown, the general consensus is that its accumulation disrupts multiple cellular events
and induces distinctive neurodegeneration (Litvan et aI., 2007b).

Genetic causes of PD

Most cases of PD are spontaneous or idiopathic in nature with a small percentage
resulting from specific genetic mutations (de Lau and Breteler, 2006). In general, familial
PD patients exhibits the same clinical picture as sporadic PD patients except for an earlier
onset in many but not all inherited cases (Gasser, 2007). Genes coding for SNCA
(SNCA), leucine rich repeat kinase 2 (LRRK2) and ubiquitin carboxyl-terminal hydrolase

Ll (UCH-Ll) are involved in autosomal dominant forms, whereas genes coding for
parkin (PRKN) , PTEN-induced putative kinase 1 (PlNKl), ATPase type 13A2
(ATP13A2), and the Parkinson's disease associated protein DJ-l (PRKN7) are involved in

autosomal recessive forms of PD (Schulz, 2008). The identification of these genes has
3

shed light on the molecular pathophysiology of the disease, but the precise role of these
genes in healthy and PD patients remains largely unknown (Hatano et aI., 2009). Most of
these genes appear to interact with one another and play roles in mitochondrial function,
oxidative stress and/or protein ubiquitination.

Identification of point mutations and genomic multiplications in SNCA, the first PD gene
to be mapped, led to the discovery that the encoded protein is the main component of
Lewy bodies, the pathological hallmark in familial and sporadic PD (Corti et aI., 2011).
SNCA is a small protein (140 KDa) whose overexpression, through duplication and
triplication of the encoding gene, is associated with neuronal toxicity in humans and in
animal models, indicating that gain-of-function mutations also contribute to the
pathogenesis of PD (Martin et aI., 2011). Recent studies demonstrate that SNCA
promotes assembly of soluble N-ethylmaleimide sensitive factor attachment protein
receptor complexes (that are required for fusion of vesicles to the presynaptic neuronal
membrane), suggesting a potential role of SNCA in dopaminergic transmission (Martin et
aI.,2011).

LRRK2 is the other gene most commonly associated with late-onset, autosomal dominant

form of familial PD (Gasser, 2007). Like SCNA, the exact function of LRRK2 in the
brain remains obscure. However, LRRK2 kinase activity is associated with cellular
toxicity and neuronal cell death and the gain-of-function point mutations of LRRK2,
observed in familial and sporadic PD, result in enhanced kinase activity (Cookson et aI.,
2007). Mutations in LRRK2 are not necessarily associated with the formation of Lewy
bodies (Funayama et aI., 2002). Nonetheless, they constitute the major genetic mutations
associated with familial PD.
4

Loss-of-function mutations in PRKN were first discovered among the Japanese to cause
autosomal recessive, early-onset familial PD with no Lewy body accumulation (Hatano et
aI., 2009). PRKN is a protein localized primarily in the cytoplasm that tags proteins for
proteosomal degradation. As an E3 ubiquitin ligase in the ubiquitin-protesome
degradation system, mutations in PRKN are postulated to impair its ability to interact
with E2 ubiquitinating enzymes, leading to the buildup of nonubiquitinated substrates
that leads eventually to neuronal cell death (Dawson and Dawson, 2010; Shimura et aI.,
2000). Like PRKN, PINK1 and DJ-1 are also responsible for autosomal recessive forms
of PD. These three genes are involved in pathways that regulate mitochondrial
morphology and function, corroborating the role of mitochondrial damage in the etiology
of PD (Corti et aI., 2011). It has been proposed that PINK1 is a protein located in the
mitochondria that interacts with DJ-1 to modulate the activity of PRKN in protein
ubiquitination (Xiong et aI., 2009). Hence, loss-of-function mutations in PINK1 hinder
the role of the encoded protein in a mitochondrial quality-control pathway, resulting in
neuronal dysfunction and death (Martin et aI., 2011). On the other hand, DJ-1 is thought
to maintain the integrity and functionality of mitochndria against oxidative stress
(Thomas et aI., 2011). DJ -1 undergoes a modification at a conserved cystein residue
before relocating into the mitochondria where it exerts its protective effect (Canet-Aviles
et aI., 2004). However, further investigations are needed to confirm the precise role of
PINK1 and DJ-1 in patients and healthy individuals.

UCH-L1 is expressed abundantly in the brain and appears to act as a deubiquitinating

enzyme and has been observed as a component of Lewy bodies in sporadic PD (Larsen et
aI., 1998; Lowe et aI., 1990). There is very little known about the physiological and
5

pathological roles of ATP l3A2 although it appears to playa role in protein degradation
via lysosomal pathways (Hatano et aI., 2009). Other PD-related genes include Htr serine
peptidase 2 (HTRA2/0Ml) that possibly plays a role in protecting neurons from oxidative

stress in a common pathway that involves PlNKl, PRKN (Tain et aI., 2009),
phospholipase A2 group VI (PLA2G6) and F-box protein 7 (FBX07) (Lesage and Brice,
2009). Taken together, whereas substantial progress has been made in the identification
of genes related to PD, relatively little is known regarding the function of these genes in
the etiology of the disease. Therefore, further investigations are needed to help elucidate
their role to pave the road for targeted therapies in the treatment of PD.

Dopamine and PD

Dopamine and acetylcholine are central components of the movement-regulating
neuronal circuits in the basal ganglia. Onset of familial and sporadic PD is characterized
by the death of dopaminergic neurons of the SNpc, resulting in diminished dopamine
release into the striatum which in turn leads to the classical motor disturbances observed
in PD. Therefore, restoring dopamine/acetylcholine balance is the primary goal of
pharmacotherapy aimed at mitigating symptoms associated with PD.

Pharmacological approaches in the treatment of PD

Levo-dopa, the precursor of dopamine, is a highly effective drug in the treatment of PD,
especially when used in the early stages. It crosses the blood-brain barrier, which
separates systemic circulation from the brain extracellular fluid, and restores dopamine
levels in the striatum of PD patients. However, levo-dopa is metabolized by the
peripheral nervous system resulting in distressing side effects such as dyskinesia, shorter
6

duration of drug-induced benefit (wearing off), and on-off pulsatile response fluctuations
associated with long-term levo-dopa. Peripheral decarboxylase inhibitors (carbidopa,
benserazide) are usually administered with levo-dopa to decrease its peripheral
metabolism and enhance its activity in the central nervous system (Olanow et aI., 2006).
Nonetheless, levo-dopa does not address the cause of PD and does not improve the nonmotor autonomic, affective and cognitive symptoms accompanying the disease.

Other anti-PD drugs include dopaminergic receptor agonists, inhibitors of dopamine
degradation, and anticholinergic agents. Dopaminergic receptor agonists act by direct
stimulation of the dopaminergic receptors in the brain and include bromocriptine,
pergolide, pramipexole and ropinirole. If used before L-dopa, they delay the onset of drug
therapy-induced dyskinesia but at the expense of poorer management of motor symptoms
(Clarke and Guttman, 2002). Inhibitors of dopamine metabolism prolong the efficacy of
levo-dopa and include monoamine oxidase B inhibitors (selegiline, rasagiline) and
catechol-o-methyltransferase inhibitors (tolcapone, entacapone). Monoamine oxidase B
inhibitors undergo extensive first-pass metabolism, resulting in production of active
amphetamine metabolites and low bioavailability, and are associated with insomnia,
psychosis

and

cardiac

arrhythmias

(Poston

and

Waters,

2007).

Catechol-o-

methyltransferase inhibitors can be added to the conventional levo-dopa/carbidopa
combination to provide better symptomatic control in PD patients (Sethi et aI., 2009).
Anticholinergic agents are less effective and act by blocking the muscarinic receptors to
restore the functional balance between dopamine and acetylcholine in the basal ganglia
(Mestre and Ferreira, 2010). They may be used alone or in combination with levo-dopa to
improve

the

motor functions

in

PD

patients.
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However,

They

may

induce

neuropsychiatric, cognitive and other typical anticholinergic side effects (dry mouth,
blurred vision, urinary retention, and cardiotoxicity) (Katzenschlager et aI., 2003).

All the aforementioned anti-PD drugs are accompanied with adverse side effects and do
not halt or reverse disease progression (Toulouse and Sullivan, 2008). More importantly,
the effectiveness of these drugs depends greatly on the functionality of the remaining
dopaminergic neurons to synthesize and secrete dopamine which decreases as the
degeneration worsens. In addition, a recent study showed that the total cost of PD were
approximately 8640 Euros per patient over a 6-month period. Anti-PD drugs were the
major component of costs paid by the health insurance companies (39.6%), constituting a
quarter of PD direct costs (Winter et aI., 2010). Another report estimated the annual cost
of prescribed drugs post-treatment initiation at $3854. However, - 67% of patients do not
adhere well to drug therapy due to the multiple dosing and regimen complexity of antiPD drugs leading to disease worsening and - $3451 annual increase in all-cause PD
associated costs (Davis et aI., 2010). Hence, there is an urgent need for new and
improved therapies that can replace or reduce the need for anti-PD medications in the
treatment of PD.
As current pharmacotherapy does not prevent the progression of PD, it is imperative that
new treatment strategies be developed that can replenish lost dopaminergic neurons
and/or prevent the loss of these neurons in affected individuals. Development of drugs
that enhance neurogenesis and/or help mobilize newly-formed neurons to the affected
brain areas is an interesting approach for the treatment of PD that needs to be further
investigated. For instance, serotonin stimulates brain-derived neurotrophic factor (a
secreted protein that enhances neurons maturation and survival) expression and the
8

administration of selective serotonin reuptake inhibitors enhances the activity of brainderived neurotrophic factor and alleviates symptoms of Huntington's disease in a mouse
model (Duan et al., 2008). Similarly, dopaminergic receptor D2 and adrenergic receptor
alfa-2 agonists and antagonists, respectively, have been shown to promote neurogenesis
in murine animals (Borta and Hoglinger, 2007; Rizk et aI., 2006). Both the excitatory
neurotransmitter glutamate and the inhibitory neurotransmitter gamma-aminobutyric acid
(GABA) play roles in neurogeneration and, hence, may be potential targets for
pharmacological intervention to treat neurodegenerative diseases (Hagg, 2009). Further,
nicotine is thought to enhance sub ventricular zone neurogenesis through the activation of
cholinergic nicotinic receptors, resulting in downstream increase of fibroblast growth
factor 2 (FGF-2). Kainic acid, however, appears to enhance FGF-2-mediated
neurogenesis through a cannabinoid receptor-l dependent manner (Aguado et aI., 2007).
Advantages of these pharmacological approaches include: (i) availability of many
candidate drugs with established safety profiles, (ii) ease of administration, and (iii) the
feasibility of withdrawing drugs in case adverse side effects and/or complications occur.
However, several impediments still exist including: (i) possible failure of these drugs due
to severe degeneration in their respective sites of action and/or due to down-regulation of
their receptors, (ii) potential side effects and/or toxicities, and (iii) lack of knowledge
regarding the precise site of action, the potentially-affected tissues and exact mechanism
of action of the drugs (Hagg, 2009). Obviously, generating small molecules that can
directly stimulate receptors of neurotrophic factors is likely to prove valuable.

Gene therapy, neurotrophic factor treatment and cell replacement therapy are all
currently being developed as potential options in combating this degenerative disorder. A

9

combinatorial strategy may be the most effective approach for replacing the
dopaminergic neurons that are lost during the course of the disease and protecting the
remaining neurons. In the following chapters, we discuss the current status of nonpharmacological approaches with a special focus on stem cell (SC) based cell
replacement therapy in the treatment of PD.
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CHAPTER II
ALTERNATIVE THERAPEUTIC APPROACHES IN PD

The failure of pharmacological agents to halt the progressive neurodegeneration in PD
has resulted in the development of alternative therapeutic approaches including brain
stimulation, neurotrophic factor-based therapies, gene therapy, fetal midbrain graft
transplantation, and SC-based therapy.

I. Deep brain stimulation

Deep brain stimulation is used in the advanced stages of PD and involves the surgical
implantation of a brain pacemaker usually in the subthalamic nucleus or the globus
pallidus pars interna. The pacemaker sends high frequency electrical impulses resulting in
the mitigation of the symptoms of PD, which in turn helps in reducing the dose of antiPD drugs. Deep brain stimulation is implemented only in advanced cases when drugtreatment is no longer effective or is accompanied by distressing side effects. Since its
approval by the food and drug administration in 2002, deep brain stimulation has
improved motor symptoms (bradykinesia, rigidity, tremors and dyskinesia) in many PD
patients for up to 5 years and appears to induce better results in L-dopa-responsive
patients with intact cognitive abilities (Bronstein et aI., 2011). However, since deep brain
stimulation requires a major surgery in the brain, and does not address or reverse the
cause of neurodegeneration, it is viewed as a less attractive approach in the treatment of
PD.
11

II. Neurotrophic factor-based therapy

Neurotrophic factors are secreted proteins that play a key role in the induction,
specification, maturation, survival and protection of neurons (Sullivan and Toulouse,
2011). Therefore, lack of neurotrophic factors has been hypothesized to contribute to the
pathophysiology of PD (Connor and Dragunow, 1998). Neurotrophic factors that act on
dopaminergic neurons include: members of the classic neurotrophin family such as brainderived neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF) family
such as GDNF and neurturin, and novel neurotrophic factors such as conserved dopamine
neurotrophic factor and mesencephalic astrocyte-derived neurotrophic factor. Of all the
identified neurotrophic factors, GDNF and neurturin have shown the most encouraging
results as therapeutic targets for degenerative disorders. Whereas the advantage of
delivering a combination of neurotrophic factors using single gene-delivery approach is
enticing, albeit controversial (Sun et ai., 2005; Zurn et ai., 1996), delivering these factors
into the brains of patients is problematic. This is because the neurotrophic factors cannot
pass the blood brain barrier and undergo rapid metabolism, raising the need for longlasting local delivery system. In addition to direct intracerebral infusion, transplantation
of neurotrophic factor-expressing cells and in vivo gene therapy have all been
implemented to deliver sufficient quantities of neurotrophic factors to the brain
(Rangasamy et ai., 2010).

Glial cell line-derived neurotrophic factor (GDNF)

GDNF is a member of the GDNF family of neurotrophic factors that also include
neurturin,

artemin

and

persephin.

The
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GDNF

family

of proteins

bind

to

glycosylphosphatidylinositol (GPI)-linked receptors called GDNF family receptors alpha
1,2 ,3 and4 (GFRul,2 ,3 and-4), and activate a transmembranous tyrosine kinase, rearranged during transfection (RET), to induce downstream signaling that includes
mitogen activated protein kinase (MAPK) and phospholipase Cy pathways (Sariola and
Saarma, 2003). GDNF has been isolated from glial cells and was confirmed to exert
neuroprotective effect on cultured dopaminergic neurons (Lin et aI., 1993). Furthermore,
GDNF has been shown to induce tyrosine hydroxylase, the rate-limiting enzyme in
dopamine synthesis, in fetal human and rat cerebral cortical cultures (Theofilopoulos et
aI.,2001).

In vivo studies have demonstrated the ability of intracerebrally-injected GDNF to protect

dopaminergic neurons and induce functional improvement in murine and primate models
of PD (Gash et aI., 1996; Tomac et aI., 1995). To inject neurotrophic factors, a
stereotactic surgery is performed after determining the precise delivery region in the brain
by co-localization studies using positron emission tomography scanning of dopamine
uptake and magnetic resonance imaging. Although open-label clinical studies showed
positive results (Gill et aI., 2003; Slevin et aI., 2007), double-blind randomized clinical
trials using intraventricular and intraputaminal infusion of recombinant GDNF showed
mild or no therapeutic benefit and were even accompanied with distressing side effects
such as nausea, vomiting, anorexia and paresthesias (Lang et aI., 2006; Nutt et aI., 2003).
These disappointing results led the sponsor (Amgen) to terminate all GDNF clinical
studies. The discrepancy between open-label and double-blind trials may be attributed to
open-label study-associated subjective evaluation bias, the exact site of injection,
variability of graft composition (the proportion of dopaminergic, serotonergic,
13

GABAergic, substance P-containing neurons and glial cells), tissue preparation
(suspension, solid tissue or strands) and/or statistical analyses.

Alternative methods of delivering GDNF include ex vivo transfected cell therapy and in
vivo gene therapy. The ex vivo transfected cell therapy approach is based on implanting

GDNF-expressing cells into the SNpc or striatum. Encapsulated GDNF-producing cell
lines have shown therapeutic results in animal models of PD (Yasuhara et aI., 2005).
Furthermore, transplantation of several primary cell lines, genetically modified to express
GDNF, have shown beneficial effects during in vivo animal studies (Behrstock et aI.,
2006; Ericson et aI., 2005). To our knowledge, no clinical trials have been conducted for
GDNF-secreting cells. On the other hand, in vivo gene delivery is aimed at delivering
GDNF continuously to the nigrostriatal system using viral vectors. Virus-based methods
of delivering GDNF circumvents the rapid metabolism of GDNF and have been shown to
induce behavioral recovery in 6-hydroxydopamine- (6-0HDA)-lesioned rats (BilangBleuel et aI., 1997; Mandel et aI., 1997). Although some success has been achieved in
animal models, clinical trials have not been warranted due to ethical and technical
concerns.

Neurturin

Neurturin belongs to the GDNF family of ligands and was identified as a survivalenhancing factor for sympathetic neurons (Kotzbauer et aI., 1996). It shares 42%
homology with GDNF and is part of a signaling pathway that involves RET -tyrosine
autophosphorylation and activation of MAPK and phosphatidylinositol 3-kinase (PI3K)
(Creedon et aI., 1997). Neurturin is expressed in the ventral midbrain and striatum and
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has been shown to enhance the survival of dopaminergic neurons in a fashion similar to
GDNF (Horger et aI., 1998).

Studies have shown the ability of cerebrally-injected neurturin to induce functional
recovery in 6-0HDA-Iesioned rats (Oiwa et aI., 2002) and I-methyl-4-phenyl-l,2,3,6tetrahydropyridine- (MPTP)-lesioned monkeys (Grondin et aI., 2008). In addition, ex vivo
transfected cell therapy, as another approach for neurturin delivery into the nigrostriatal
system, via the intracerebral implantation of genetically-modified cells has been
exploited. Neural stem cells (NSCs) overexpressing neurturin showed neuroprotective
effects and induced functional recovery in a rat model of PD (Liu et aI., 2007). Another
approach to deliver neurturin continuously to the brain is in vivo viral-based neurturin
gene delivery to the SNpc and has shown efficacy in protecting dopaminergic neurons of
the nigrostriatal pathway in rats (Fjord-Larsen et aI., 2005) and monkeys (Kordower et
aI.,2006).

In an open-label clinical trial, CEREI20, an experimental adeno-associated VIruS 2
(AAV2) vector carrying the gene for human neurturin and developed by Cere gene Inc.,
was bilaterally injected into the putamen of 12 patients (Marks et aI., 2008). No serious
side effects were reported and improvement in off-medication Unified Parkinson's
Disease Rating Scale (UPDRS) was observed. UPDRS is a common scoring system first
developed in the 1980s that comprehensively examines the mood, mental state, daily
activities, and motor symptoms in patients in order to quantify the severity of PD. Each
question used in UPDRS, that has to be answered by the patient or by the caregiver,
assesses the severity of a PD symptom on a scale of 0-4 (0
3

= moderate,

4

= severe).

= normal,

1= slight, 2 = mild,

A newer verSIOn of UPDRS, revised by the movement
15

disorder society, rates 65 items with a 0-4 value whereas the older version rates 55 items,
47 with a 0-4 value and 7 items with yes or no (Goetz et aI., 2008).

Following the CERE120-open label study, a double-blind randomized multicenter trial of
58 patients showed failure of bilateral intraputaminal injection of CERE-120 to reach the
primary endpoint with no therapeutic differences observed between controls and treated
PD patients at 12 months post-therapy. However, a longer-term follow-up study on a
subgroup of the same patients revealed a modest clinical improvement at 18 months posttherapy. Additionally, subsequent post-mortem investigation on 2 patients, who died for
reasons unrelated to the treatment, revealed that neurturin expression was limited to the
putamen, indicating limited retrograde transport of neurturin through the degenerated
nigrostriatal neurons to the SNpc. To circumvent the deficiency in retrograde transport,
Ceregene has decided to initiate another CERE-120-based phase II trial that targets both
the putamen and the SNpc (Marks et aI., 2010). The results of the trial have not been
revealed at the time of writing.

Brain-derived neurotrophic factor

Brain-derived neurotrophic factor is widely expressed in the brain and plays a critical role
in the axonal growth and neuronal regeneration (Lykissas et aI., 2007). Whereas several
studies report brain-derived neurotrophic factor to have neuroprotective effects in
chemically-induced nigrostriatal dopaminergic neuron injury; it also supports neuronal
maturation under homeostatic conditions (Baker et aI., 2005). It acts by interacting with
two receptors abundantly expressed in the nigrostriatal system, tyrosine kinase B (TrkB)
and p75 neurotrophin receptor (p75NTR) (Yan et aI., 1997).

16

Ex vivo and in vivo strategies, for delivering brain-derived neurotrophic factor into the

brain, have been investigated. Astrocytes and fibroblasts, genetically modified to express
brain-derived neurotrophic factor and injected intrastriatally in a rat model of PD,
resulted in functional motor improvement (Levivier et al., 1995; Yoshimoto et al., 1995).
However, in vivo gene transfer of brain-derived neurotrophic factor gene into the SNpc of
parkinsonian rats failed to exhibit neuroprotective properties (Klein et al., 1999; Sun et
al., 200S), indicating the insufficiency of brain-derived neurotrophic factor single-gene
delivery. Moreover, supraphysiological amounts of brain-derived neurotrophic factor
could be associated with deleterious effect on neuronal circuits, impaired learning, and
increased susceptibility to seizures (Croll et al., 1999). The mixed results observed with
brain-derived neurotrophic factor therapy were not convincing enough to warrant
conducting clinical studies. Besides GDNF, neurturin and brain-derived neurotrophic
factor, the utility of several other growth factors, including vascular endothelial growth
factor, pigment epithelium-derived factor, growth/differentiation factor S, neurotrophin-3,
neurotrophin-4/S, conserved dopamine neurotrophic factor and mesencephalic astrocytederived neurotrophic factor, in the treatment of PD has been and/or is being explored
(Falk et al., 2010; Lindholm et al., 2007; Sullivan et al., 1997; Ventimiglia et al., 1995;
Voutilainen et al., 2009).

Lately, the focus is shifting to implanting genetically-engineered neurotrophic factorexpressing SCs to replace dead dopaminergic neurons and simultaneously protect the
remaining neurons in patients. Another potentially-effective approach is the use of small
molecules to enhance the activity of endogenous neurotrophic factors. For instance, it
was demonstrated that intracerebral infusion of peroxovanadium, an inhibitor of protein
17

tyrosine phosphatases, can protect neurons in the SNpc of 6-0HDA-Iesioned rats by
enhancing the activity of endogenous neurotrophic factors on their respective tyrosine
kinase-linked receptors (Yang et aI., 2007). Creating small molecules that could directly
activate neurotrophic factor receptors would be of great interest as well.

III. Gene therapy

Gene therapy in PD offers the advantage of delivering therapeutic genes into specific loci
in the brain using a one-time stereotaxic surgical procedure, resulting in robust long-term
gene expression. Gene therapy primarily aims at achieving one or more of the following
three goals. The first goal is to boost the production of dopamine into the striatum by
over-expressing dopamine synthesizing enzymes such as tyrosine hydroxylase (Zhang et
aI., 2004) and aromatic L-amino acid decarboxylase (AADC) (Li et al., 2006). The
second goal is to protect the remaining dopaminergic neurons in the basal ganglia by
utilizing genes of neurotrophic factors such as GDNF (Akerud et aI., 2001) and neurturin
(Fjord-Larsen et aI., 2005). The third goal is to modulate basal ganglia circuits through
the introduction of glutamic acid decarboxylase (GAD), the enzyme that converts
glutamic acid into inhibitory GABA, in the subthalamic nucleus (Emborg et aI., 2007).
AA V and lentiviruses (LV) are typically used to introduce the genes of interest into the
striatum, SNpc or subthalamic nucleus cells of PD patients, using direct stereotaxic
injections. AA V vectors are preferred in PD clinical trials due to their low
immunogenicity and ability to induce potent, long-term expression of genes (Zaiss and
Muruve, 2005). Similarly, LV constructs offer a safe clinical-grade alternative to deliver
genes into non-dividing cells in neurodegenerative disorders (Lundberg et aI., 2008).
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The gene coding for tyrosine hydroxylase is the first gene to be investigated in the quest
for a gene therapy of PD, and has shown promising results in vitro and in vivo (Kang et
aI., 2001). Further, levels of AADC, the enzyme that catalyzes the decarboxylation of
levo-dopa and converts it to DA, are diminished in the brains of PD patients. Indeed,
AADC gene therapy has been shown to improve motor functions in MPTP-Iesioned
primates (Bankiewicz et aI., 2006). These results led to the initiation of phase I clinical
trials. Ten PD patients were treated with bilateral intraputaminal injection of human
AADC-carrying AA V vector and displayed approximately 30% improvement in the onmedication (at day times of drug peak plasma concentration such as one hour after taking
a drug dose) and off-medication (at day times of lowest drug plasma concentration such
as early morning) states based on the UPDRS. However, headaches and increased risks
of cerebral hemorrhage were reported as side effects (Christine et aI., 2009). Another
phase I clinical study employing AA V-mediated intraputaminal delivery of AADC
carried out in 6 PD patients were well tolerated and 46% improvement in functional
performance in the off-medication state, based on the UPDRS scores was reported
(Muramatsu et aI., 2010).

A combinatorial approach involving infusion of the three main enzymes required in
dopamine synthesis, viz. TH, guanosine triphosphate (GTP) cyclohydrolase 1, and
AADC using a tricistronic LV vector resulted in significantly higher motor recovery in
primate models of PD, compared to single gene delivery (Jarraya et aI., 2009; Muramatsu
et aI., 2002). GTP cyclohydrolase 1 is an enzyme needed to convert GTP to
tetrahydrobiopterin (BH4), a cofactor involved in the tyrosine hydroxylase-catalyzed
production of levo-dopa from L-tyrosine (Levine et aI., 1981). Pre-published reports on a
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currently ongomg phase IIII clinical trial, that implements a similar combinatorial
strategy, revealed motor improvement in UPDRS scores in all cohorts at 6 months post
therapy (Oxford BioMedica, 2011), highlighting the advantage of combinatorial
approaches over single gene delivery. A schematic representation of the tricistronic
approach is shown in figure 2.
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Since PD pathology is associated with overactivity of the subthalamic nucleus and the
globus pallidus pars intern a (Hammond et aI., 2007), it was hypothesized that inhibiting
the subthalamic nucleus through introduction of the GAD gene that converts glutamic
acid into GABA, the major inhibitory transmitter in the eNS, will alleviate the symptoms
of PD (figure 3). Indeed, functional improvements have been reported following AA V2mediated delivery of GAD gene in murine (Lee et aI., 2005) and primate (Emborg et aI.,
2007) models of PD, leading to the commencement of clinical trials . In a phase I trial of

unilateral infusion of the GAD-viral vector into the subthalamic nucleus, no adverse
effects were reported and significant motor improvements were observed up to 12 months
post-treatment (Kaplitt et aI., 2007). In addition, a recent double-blinded clinical trial
implementing the AA V2-mediated bilateral subthalamic nucleus delivery of GAD
showed positive results with a 23.1 % mean improvement of UPDRS motor score in the
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off-medication state, cQmpared to 12.7% in the control group at 6 months post-treatment
(LeWitt et aI., 2011). These results are probably the most promising results observed in a
controlled double-blinded trial in the search for an effective gene therapy for PD.
However, the improvement shown in the GAD-delivery study seem to be approximately
half of what was observed with surgical deep brain stimulation (Limousin et aI., 1998),
raising skepticism about the future of gene-therapy approaches in PD.

inhibition

Figure 3. lnhibiting the subthalamic nucleus (STN) and/or the globu~ pallidu~ interna via deep brain
stimulatioll or via delivery of glutamic acid decarboxylase encoding gene is useful to treat PD.

Taken together, these studies indicate the potential for using gene therapy to treat PD in
the future. However, improved long-term stable expression of target gene as well as
confirmation of their safety are required for the success of effective and safe genetherapy approaches in the treatment of PD.

21

CHAPTER III
CELL REPLACEMENT THERAPY FOR PD

The failure of known pharmacological and surgical measures to halt and/or reverse the
progressive loss of neurons and the associated pathophysiology in PD patients makes it
imperative to search for novel therapeutic approaches. Cell replacement therapy appears
to be promising in this regard as it offers a means to replace degenerative dopaminergic
neurons, especially in the SNpc, where the initial neurodegeneration occurs in PD (Chiu
and Hall, 2006). Double-blind placebo-controlled clinical trials that implemented the
intracerebral implantation of human dopaminergic neurons-containing grafts in several
PD patients (Freed et aI., 2001; Olanow et aI., 2003) provided proof-of-principle for the
potentials of cell replacement therapy in PD, albeit with a few remaining challenges.

I. Tissue grafts

The earliest cell replacement therapy for PD employed autologous chromaffin cellcontaining adrenal medulla tissue and was reported as a success when grafted in 2 PD
patients (Madrazo et aI., 1987). Subsequently, hundreds of patients were grafted based on
the same approach. However, the grafts were found to be a failure due to the associated
morbidity and the lack of significant behavioral recovery (Goetz et aI., 1991).

The trend then shifted toward grafting fetal mesencephalic tissue collected from 8- to 9week-old fetuses (Lindvall et aI., 1990). The first clinical trials implementing fetal tissue
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grafting was carried out more than twenty years ago and showed promising recovery in
some patients (Lindvall et aI., 1990). Furthermore, fetal mesencephalic graft neurons
survived in the host striatum for a long period of time and induced positive motor
improvement (Hagell et aI., 1999; Hauser et aI., 1999). In fact, some patients improved
satisfactorily for more than ten years after the transplantation (Mendez et aI., 2008).
However, double-blind fetal midbrain grafting studies sponsored by the National Institute
of Health (NIH) showed variable effects as well as induction of distressing side effects
such as graft-induced dyskinesia. Indeed, graft-induced dyskinesia was reported in 56%
of the treated subjects and some cases necessitated surgical intervention by deep brain
stimulation (Freed et aI., 2001; Olanow et aI., 2003). Advanced PD patients with
widespread neurodegeneration outside the nigrostriatal system and those with a history of
levo-dopa-induced dyskinesia are more likely to experience graft-induced dyskinesia.
Hence, it is imperative to apply strict inclusion criteria that avoid patients with high risk
of developing graft-induced dyskinesia (Wakeman et aI., 2011). The cause of the
dyskinesia is likely the "overload" due to excess dopamine secretion into the striatum
and/or the unavoidable presence of serotonergic neurons within the fetal ventral
mesencephalic grafts (Lane et aI., 2010). In fact, serotonergic neuron-rich grafts do not
exert therapeutic effect and cause deterioration of levo-dopa-induced dyskinesia in a rat
model of PD (Carlsson et aI., 2007). Moreover, a 2: 1 ratio of dopaminergic neurons to
serotonergic neurons markedly reduced levo-dopa induced dyskinesia, indicating that the
relative ratio of dopaminergic neurons to serotonergic neurons (not the absolute number
of serotonergic neurons) is what drives dyskinesia (Carlsson et aI., 2009). Interestingly,
systemic administration of buspirone, a serotonergic receptor 5-HTIA agonist that
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dampen transmitter release from serotonergic neurons, markedly attenuated graft-induced
dyskinesia (Politis et aI., 2010). Hence, it is recommended to exclude, as much as
possible, serotonergic neurons from transplants. Moreover, standardization of the
parameters for graft collection, preparation and storage

IS

needed to control the

dopaminergic: serotonergic composition of grafted tissues.

Importantly, detection of cellular PD-related pathological features in a few grafted cells
in the brains of treated patients, ten years after transplantation (Kordower et aI., 2008; Li
et aI., 2008), led to the conclusion that the surrounding brain microenvironment has a
deleterious effect on the survival of grafted and endogenous dopaminergic neurons in PD
patients. This report was contradicted by another study which did not detect any
pathological features in the grafted neurons (Mendez et aI., 2008). Nevertheless, ethical
concerns as well as issues associated with the availability of 8-9 week old fetal tissue
made it impractical to continue investigating fetal midbrain-derived grafts in clinical
therapy (Astradsson et aI., 2008; Deierborg et aI., 2008), raising the need for more
practical sources for cell replacement therapy in PD.

II. Stem cells (SCs) as a source of cell replacement therapy in the treatment of PD

The ethical and practical impediments associated with fetal grafting in PD shifted the
attention of the cell replacement therapy field to the use of SCs, widely viewed as a
therapeutic strategy with immense potential in the treatment of neurodegenerative
diseases. The general strategy is to harvest SCs and induce them to differentiate into
dopaminergic neurons that could be transplanted in the brain to replace, protect or repair
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endogenous dopaminergic neurons

III

the SNpc

III

order to halt and/or reverse the

progressive nature of the disease.

Over the past decade, several types of SCs have been investigated as potential candidates
for cell replacement therapy in PD, including pluripotent embryonic SCs (ESCs), induced
pluripotent SCs (iPSCs), and multipotent neural (N) and mesenchymal (M) SCs.
Pluripotent SCs, such as ESCs, give rise to all cell types within the three germ layers,
whereas multipotent tissue-specific SCs such as NSCs give rise to all cell types within
their respective tissue. There is some evidence that multipotent SCs possess the ability to
trans differentiate when given the right conditions, albeit with little efficiency (Cogle et
aI., 2004; Priller et aI., 2001), indicating the possibility of using non-neural multipotent
SCs, such as MSCs, to induce dopaminergic neuronal differentiation in the treatment of
PD. A summary of the different types of stem cells investigated in the treatment of PD
and their advantages and disadvantages are presented in table 1.
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fahle 1. Summar:v of tl1(' a(hantag('s and disadvantage of stern n-II" im esl.igated in the treatment of
PD.

Type

potency

Main source

Advantages

Disadvantages

embryonic
stem cells

pluripotent

embryonic blastocyst

- high dopaminergic
yield

- tumorigenic
- ethical issues

induced
pluripotent
stem cells

pluripotent

reprogrammed
somatic cells

- effective in animal
models

- poor survival in vivo

- autologous
transplantation

- low dopaminergic
yield

- no ethical issues

- time consuming

- effective in animal
models

- labor intensive
- costly
- tumorigenic
- poor survival in vivo

mesenchymal
stem cells

multi potent

bone marrow and
umbilical cord

- autologous
transplantation

- low dopaminergic
yield

- possess antiinflammatory properties

- poor survival in vivo

- not tumorigenic
- safe
- effective in animal
neural stem
cells

multipotent

adult brain

- autologous
transplantation

- low dopaminergic
yield

- differentiate into the
three lineages of the
nervous system

- poor survival in vivo

- effective in animal
models
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- hard to identify and
isolate
- tumorigenic

IIa. Embryonic Stem Cells

ESCs are derived from the inner cell mass of the blastocyst (figure 4) and are
characterized by self-renewal (indefinite proliferation while maintaining their identity),
and pluripotency (ability to differentiate into all cells of the three germ layers). The main
advantages of ESCs as a source for cell replacement therapy in PD are their pluripotency
and high rate of proliferation (Newman and Bakay, 2008). So far, among all types of
SCs, ESCs have yielded the most promising results in terms of their efficiency to
differentiate into dopaminergic neurons . In fact, protocols for inducing dopaminergic
neuronal differentiation of SCs have mostly been developed using ESCs (Perrier et aI.,
2004; Schulz et aI., 2004; Yan et aI., 2005).

Zygote

Blastocyst

Figure .... When the Iygnle i~ formed during conception, il ~Iarl~ In diVIde rapidly and
Emhryonie stem cells are derived from lhe inner cell mass of the hlastocyst.

form~

lhe hlastoc)sl.

To achieve best results, ESCs must gIve n se to A9-subtype midbrain dopaminergic
neurons that could replace or prevent the progressive loss of dopaminergic neurons in the
SNpc region of PD patients (Mendez et aI., 2005). Hence a major focus has been placed
on inducing ESCs to differentiate into dopaminergic neurons before injecting them into
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the patient midbrain. The differentiation of SCs into dopaminergic neurons is promoted
by culturing them on stromal feeder layers (Kawasaki et aI., 2000), in the presence of
specific dopaminergic neuronal fate-driving growth factors such as sonic hedgehog
(SHH) (a regulator of cell division and organogenesis) and FGFS (Lee et aI., 2000),
and/or through the expression of transcription factors such as Lmxla and Nurrl
(transcription factors that play an active role in the differentiation of midbrain precursors
into dopaminergic neurons) (Andersson et aI., 2006; Kim et aI., 2002). Not only do
growth factors promote neuronal differentiation but they also potentiate the survival rate
of grafted cells, thus inducing better functional recovery in animal models of PD. For
instance, adding FGF2, FGF20 and Wnt5a to parthenogenetic primate SCs at their final
stages of differentiation enhance survival of the grafted cells and consequently, improve
motor function in 6-0HDA-Iesioned rats (Sanchez-Pernaute et aI., 200S). The highest
differentiation efficiency has been achieved using genetically-modified Nurr 1overexpressing mouse ESCs, co-cultured with PA6 stromal cells in a medium enriched
with shh, fgfS and ascorbic acid (Kim et aI., 2006). The study resulted in -90%
dopamine-secreting neurons that integrated successfully upon transplantation in the brain
of a rat model of PD.
In vivo studies have revealed the ability of ESCs to differentiate efficiently into

dopaminergic neurons which in turn could be used to treat parkinsonian symptoms in
animal models. For instance, upon transplantation of ESC-derived dopaminergic neurons
in the striatum of unilaterally 6-0HDA-Iesioned rats, Rodriguez-Gomez et aI. confirmed
appropriate dopamine release and reuptake by the transplanted cells as well as their
ability to stimulate postsynaptic dopaminergic D2 receptors (Rodriguez-Gomez et aI.,
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2007). Importantly, the study showed that the implanted dopaminergic neurons survived
for 32 weeks after transplantation and induced marked behavioral recovery. Similarly,
over 70% reductions in chemical-induced rotational behavior and improved motor
function were observed when ESC-derived dopaminergic neurons were implanted
intrastriatally in a rat model of PD (Barberi et aI., 2003). In primates, ESCs co-cultured
with PA6 cells in the presence of FGF2 and FGF20 differentiated successfully into
dopaminergic neurons, that survived in the brain and improved neurological deficits upon
transplantation in the striatum of MPTP-Iesioned monkeys (Takagi et aI., 2005).
Whereas the aforementioned studies show marked behavioral recovery in animal models
of PD when transplanted with non-human neurons, use of human (h) ESC-derived
dopaminergic neurons have yielded less encouraging results, probably due to
histocompatibility issues. Groups who transplanted dopaminergic neurons derived from
hESCs into the brains of hemiparkinsonian rats have reported either no therapeutic effect
(Brederlau et aI., 2006; Park et aI., 2005) or modest functional improvement (Ben-Hur et
aI., 2004). Although Roy et aI. reported long-term survival of many brain-grafted hESCderived cells in addition to a significant functional recovery in a rat model of PD (Roy et
aI., 2006), subsequent studies questioned the results and conclusions drawn from the
study and have suggested that the behavioral improvement observed was not dopaminedependent but probably due to graft-induced striatal damage (Morizane et aI., 2008).
More recently however, Kriks et aI. were able to extend the in vivo survival of midbrain
dopaminergic neurons derived from hESCs up to 5 months and these neurons were able
to induce significant motor improvement in parkinsonian mice, rats and monkeys (Kriks
et aI., 2011). This group proposed a novel protocol for deriving human dopaminergic
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neurons from ESCs that recapitulated physiological conditions of dopaminergic neuronal
development, thereby enhancing their long-term survivability both in vitro and in vivo.

Several challenges are still facing the clinical application of ESC-based therapy in PD
patients. To our knowledge, almost all previous investigations have reported poor
survival of hESC-derived neurons following transplantation (Brederlau et aI., 2006; Park
et aI., 2005), probably due to immunological rejection by the host tissues (Toriumi et aI.,
2009). To circumvent this issue, some studies emphasize the importance of identifying
the optimal developmental stage of ESC-derived cells before transplantation. In this
regard, dopaminergic neuronal precursors are thought to be more capable of avoiding the
premature death of cells after transplantation as compared to the mature dopaminergic
neurons (Jonsson et aI., 2009). Moreover, ethical concerns associated with the use of cells
obtained from human embryos for cell replacement therapy have made clinical
application of ESCs difficult (Fukuda and Takahashi, 2005).

In addition to the aforementioned impediments, the risk of teratoma (potentially fatal
benign tumors containing a mixture of tissue types, formed after injection of SCs in
animal models) formation after transplanting ESC-derived transplants poses the greatest
challenge to clinical cell replacement therapy for PD patients. In fact, human ESCs share
many cellular and molecular similarities with cancer cells such as high proliferative
potential (Amit et aI., 2000), genomic instability (Harrison et aI., 2007), epigenetic status
(Calvanese et aI., 2008), and high telomerase activity (Hiyama and Hiyama, 2007).
Therefore, it is generally accepted that in vitro differentiation of ESCs into more mature
dopaminergic precursors or neurons must be carried out before grafting. Furthermore,
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excluding all undifferentiated ESCs before transplantation is essential to avoid the
formation of teratomas.

A number of approaches have been proposed to eliminate undifferentiated ESCs. For
instance, fluorescence-activated cell sorting (FACS) techniques have been implemented
to exclude undifferentiated SCs and neural precursors based on cell surface markers
(Fukuda et aI., 2006). A second approach to eliminate pluripotent cells involves killing
them through the use of cytotoxic antibodies (Tan et aI., 2009) or induction of selective
apoptosis of undifferentiated cells through the use of the cerami de analogue, N-oleoyl
serinol (S 18) (Bieberich et aI., 2004). A third approach involves Cripto, a protein known
to inhibit ESCs differentiation and enhances tumorigenicity after transplantation. Indeed,
Cripto knockout ESCs have been shown to differentiate successfully into dopaminergic
neurons without inducing tumorigenesis when implanted into 6-0HDA-Iesioned rats
(Parish et aI., 2005). Novel approaches based on studies addressing the molecular basis of
tumorigenesis will enable suppression of tumorigenic genes in ESC-derived neurons in
transplantation therapy.

lIb. Induced Pluripotent Stem Cells

The discovery of iPSCs has presented an invaluable source for cell replacement therapy
that avoids the ethical issues associated with the use of ESCs. The general concept of
using iPSCs in the treatment of PD is to reprogram the patient's own adult somatic cells
into a pluripotent state and then induce them to differentiate into dopaminergic neurons
that could be transplanted into the patient's brain (figure 5). Mouse somatic fibroblasts
were the first to be reprogrammed into iPSCs through retroviral transduction of four
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transcription factors, namely octamer-binding transcription factor 4 (Oct4), SRY boxcontaining gene 2 (Sox2), Kruppel-like factor 4 (Klf4), and c-Myc (Takahashi and
Yamanaka, 2006; Wernig et aI., 2007). In addition to fibroblasts, several other cell
lineages have subsequently been reprogrammed into a pluripotent state by overexpressing
some or all of the aforementioned four transcription factors (Golestaneh et aI., 2009;
Kunisato et aI., 2010; Yamanaka et aI., 2008). Newer reprogramming protocols such as
methods requiring no viral integration as well as strategies using small molecules to
promote reprogramming efficiency are being developed to enhance the clinical potential
of iPSCs, raising the possibility that they may replace ESCs in cell replacement therapy
in the near future (Nishikawa et aI., 2008; Wernig et aI., 2008; Yamanaka, 2008).

The iPSCs are similar but not identical to ESCs in morphology, proliferative potential,
telomerase activity, cell surface markers, gene expression, and epigenetic status (Kim et
aI., 2010; Takahashi et aI., 2007). Although micro array studies have shown that iPSCs
exhibit a gene-expression profile that is similar to ESCs (Hochedlinger and Plath, 2009),
they are less robust than ESCs in terms of differentiation potential and effectiveness in
cell replacement therapy. In fact, an increased body of literature shows that iPSCs exhibit
their own unique gene expression and DNA methylation pattern that are different from
ESCs (Chin et aI., 2009; Doi et aI., 2009). These small differences might be attributed to
the genomic integration of reprogramming transcription factor genes or to the unique
genetic makeup of the cells prior to reprogramming.
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Figure 5. Transduction of four transcnplillfl factors into fibroblasts result~ in the forillation of induced
pluripotent stem cells which can subsequently be inLluced to differentiatc into dopaminergic neurons to
replace L1egeneratcLi neuron~ ill Parkinson's disease.

The iPSC technology offers a number of advantages for cell replacement therapy in PD.
First, it avoids the ethical controversies associated with the use of ESCs in cell
replacement therapy for PD. Furthermore, the use of iPSCs makes it feasible to carry out
autologous transplantation, thereby eliminating the risk of graft rejection by the recipient
immune system (Dimos et aI., 2008; Park et aI., 2008b). In fact, iPSCs obtained from PD
patients have been shown to differentiate as efficiently as healthy individual-derived
iPSCs and displayed no PD-related pathological features in vitro (Soldner et aI., 2009).
When PD patient' s iPSC-derived cells were intrastriatally transplanted in a murine model
of PD, substantial attenuation of motor deficits were observed up to 16 weeks after
transplantation (Hargus et aI., 2010). Although further studies are needed to establish
their long-term functionality, these exciting observations highlight the curative potential
of iPSCs and justify their use as a viable cell replacement strategy in the treatment of PD.
Several in vivo studies have shown promising results with the use of iPSCs in the
treatment of PD. For instance, Wernig et aI. managed to promote the differentiation of
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iPSCs into neuronal precursors and dopaminergic neurons in vitro. Following subsequent
in vivo implantation, iPSC-derived cells migrated into several brain tissues, integrated
properly, and improved behavioral recovery in 6-0HDA-lesioned rats. Although initial
observations showed the occurrence of teratomas in the grafted areas, depletion of all
undifferentiated cells using FACS resulted in functional improvement without tumor
formation up to 8 weeks after transplantation (Wernig et aI., 2008). More recently,
Swistowski et al. were successful in generating dopaminergic neurons from human
(h)iPSCs, and the intracerebrally transplanted neurons survived and improved
parkinsonian symptoms in a rat model of PD (Swistowski et aI., 2010). Similar results
were obtained by Cai et al. by transplantation of commercially available hiPSCs linederived dopaminergic progenitor cells into the brains of 6-0HDA-lesioned rats (Cai et
al.,201O).

As with any new emergent technology, the iPSC technology also suffers from several
technical and safety limitations that hinder its clinical use in patients with PD. For
example, progenitors derived from hiPSCs are prone to earlier senescence than those
from hESCs (Feng et aI., 2010). Furthermore, compared to hESCs, hiPSCs differentiate
into midbrain dopaminergic neurons with very low efficiency, rendering the clinical
application of iPSCs costly and impractical. The low dopaminergic yield obtained from
iPSCs may be attributed to the activation of anti-reprogramming or tumor-suppressive
cellular mechanisms (Chen et aI., 2011). In addition, integration of viral genomic material
in the iPSCs may also playa role in altering their differentiation potential.

Due to their pluripotent potential, engrafted iPSCs also exhibit a tendency to generate
teratomas comprised of the three fetal germ layers (Takahashi et aI., 2007; Takahashi and
34

Yamanaka, 2006). In fact, several recent reports indicate a higher tumorigenicity risk
associated with iPSCs than with ESCs (Gutierrez-Aranda et aI., 2010; Ohm et aI., 2010).
In addition to pluripotency-related tumorigenesis, tumor formation may also occur as a
result of genomic integration of the viral vector DNA into the iPSCs and/or due to the
mitogenic properties of the transcription factors used in reprogramming (Gottweis and
Minger, 2008). In fact, two of the four reprogramming transcription factors, namely cMyc and Klf4, are oncogenic and several protocols have been proposed to minimize or
avoid their use in reprogramming. Fortunately, c-Myc-free reprogramming protocols
have been tested and proven successful in generating iPSCs, albeit slower and less
efficient (Nakagawa et aI., 2008). Furthermore, Oct4 and Sox2 are sufficient for
reprogramming human fibroblasts without the need for c-Myc or Klf4, when valproic
acid, a histone deacetylase inhibitor, was present (Huangfu et aI., 2008). These
observations, together with the potential use of small molecules in generating iPSCs,
raise the possibility of minimizing or eliminating the need for oncogenic factors in cell
reprogrammmg.

Since the use of integrating retroviruses m reprogrammmg

IS

also associated with

tumorigenicity (Yu et aI., 2007), attempts have been made to generate iPSCs through the
use of nonviral or nonintegrating viral vectors, albeit with lower efficiency. Jia et aI. used
DNA minicircle vectors, supercoiled molecules primarily composed of eukaryotic
expression cassette, to generate trans gene-free iPSCs from human adipose SCs (Jia et aI.,
2010). The resulting minicircle iPSCs subclones showed a high degree of similarity to
hESCs in global gene expression with no genomic integration of the transgenes.
However, the reprogramming efficiency achieved (-0.005%) was lower than that of viral35

based reprogramrrung (-0.01 %). In addition, removmg reprogramrrung transcription
factors after reprogramrrung using Cre-recombinase excisable viruses has been
accomplished (Soldner et aI. , 2009). The resultant factor-free hiPSCs maintained a
pluripotent state and showed an overall transcription profile closely related to hESCs
rather than that of transgenic hiPSCs. More recently, induction of iPSCs was achieved
through the use of protein-based programming without the need for gene-manipulation
(Cho et aI. , 2010). The study proposed that transfer of ESC-derived proteins into mouse
fibroblasts could result in reprogramming to a pluripotent state without the risk of
tumorigenicity associated with the use of exogenous transcription factors. Other non viral
or nonintegrating viral vectors recently used to generate iPSCs include non-integrating
adenoviruses (Stadtfeld et aI. , 2008), plasmids (Okita et al. , 2008), episomal vectors (Yu
et aI. , 2009) , synthetic modified rnRNA (Warren et aI. , 2010), piggyBac transposition
(Woltjen et aI. , 2009) , and miRNA (Anokye-Danso et al. , 2011 ). Selected methods for
reprogramming cells into iPSCs are presented in table 2.

Table 2. Some methods for reprogramming human and murine somatic cells into iPSCs and their
efficiencies. if available.

Source of iPSCs
human and embryo nic
somatic cell s

Reprogramming method
miRNA-medi ated
reprogramming

human adipose stem
cells

nonviral DNA minicircle
vectors carrying OCT4, SOX2,
NANOG, and L1N28

multiple human cell
types

synthetic modified mRNA

mouse cardi ac
fibroblasts

protein-based reprogramming
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Reprogramming
efficiency

Refs.

2: 0. 1%

Anokye-Danso et aI. ,
2011

0.005 %

Ji a et aI. , 2010

1.4%

W arren et aI. , 2010

Cho et aI. , 2010

mouse adult bone
marrow mononuclear
cells

retroviral transduction of oct4,
sox2, klf4, and c-myc

0.067%

Kunistao et aI., 2010

human adult testes

embryonic stem cell medium
enriched with appropriate
growth factors (basic FGF)

0.5-1 %

Golestaneh et aI., 2009

human PD patients
fibroblasts

cre-recombinase excisable
lentiviral viruses transducing
OCT4, SOX2, KLF4, and CMYC

0.01%

Soldner et aI., 2009

human PD patients
fibroblasts

cre-recombinase excisable
lentiviral viruses transducing
OCT4, SOX2, and KLF4

0.005%

Soldner et aI., 2009

human and murine
embryonic fibroblasts

doxycycline-inducible
transcription factors delivered
by PiggyBac transposition

mouse embryonic
fibroblasts

plasmids containing the
complementary DNA for oct4,
sox2, klf4, and c-myc

< 0.000029%

Okita et aI., 2008

mouse fetal liver cells

nonintegrating adenoviruses
expressing oct4, sox2, klf4, and
c-myc

0.0001-0.001 %

Stadtfeld et aI., 2008

human fibroblats

retroviral transduction of OCT4,
SOX2, and KLF4, in the
presence of valproic acid

1%

Huangfu et aI., 2008

human fibroblasts

< 0.001%

Nakagawa et aI., 2008

human PD patients
fibroblasts

retroviral transduction of OCT4,
SOX2, and KLF4
retroviral transduction of OCT4,
SOX2, KLF4, and C-MYC

mouse somatic
fibroblasts

retroviral transduction of oct4,
sox2, klf4, and c-myc

0.05-0.1%

WoItjen et aI., 2009

Park et aI., 2008b

Wernig et aI., 2007

Another interesting approach to eliminate tumorigenicity of iPSCs is the direct
reprogramming of somatic fibroblasts into dopaminergic neurons, thereby avoiding the
formation of potentially tumorigenic pluripotent SCs (figure 6). To that end, mouse
fibroblasts were directly reprogrammed in vitro to become neurons, without passing
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through a potentially tumorigenic pluripotent state, by employing the transduction of
three neural-lineage-specific transcription factors Ascll, Mytll and Bm2 (Vierbuchen et
aI., 2010). The resultant neurons exhibited excitatory phenotype with cortical identity and
formed functional synapses. Although the efficiency of reprogramming reached 19.5%,
tyrosine hydroxylase-expression was not detected, indicating that dopaminergic neurons
were not induced. Nonetheless , the study paves the road for more investigations to use
neural cell-fate determining proteins to directly reprogram somatic cells into
dopaminergic neurons.

direct
reprogran:nning

Figure 6. Direct reprogramming of lihrohlasls into
tumorigenic induced pluripotent stem cell),.

ncuron~

has the advantage of avoiding the formation of

The iPSC technology is labor-intensive, time-consuming and costly. Increasing the
efficiency of reprogramming could help reduce the cost of generating iPSCs. To that end,
more efficient protocols must be developed in the near future to advance the role of
iPSC-based therapy in degenerative disorders. Interestingly, a recent report has indicated
that miRNA could influence cellular reprogramming and generation of iPSCs.
Consequently, small molecules promoting or inhibiting specific miRNAs may prove
valuable in enhancing the efficiency of cellular programming (Mallanna and Rizzino,
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2010). In addition to reducing the cost of iPSC technology, it is also imperative to
understand and to circumvent the early senescence and tumorigenicity associated with
iPSC-derived cells.

lIe. Mesenchymal Stem Cells

The use of MSCs in the quest for a cell replacement therapy -based treatment for PD is
relatively new and less well-characterized. MSCs are responsible for generating tissues of
the mesoderm and reside in adult (e.g. bone marrow, adipose tissue, peripheral blood, and
liver), fetal (e.g. bone marrow, lung, spleen, liver, brain, and peripheral blood), and extraembryonic tissues (e.g. umbilical cord blood, amniotic fluid, and placenta). However, the
main sources for cell replacement therapy are the umbilical cord and the adult bone
marrow (Zhao and Xu, 2011). The multipotent MSCs normally differentiate into
mesodermal osteocytes, adipocytes, chondrocytes, and myocytes and can also give rise to
neuroectodermal neurons under the right conditions in vitro (Pittenger et aI., 1999;
Sanchez-Ramos et aI., 2000; Woodbury et aI., 2000). MSCs have been shown to have
inherent ability to repair neuronal damage (Phinney and Isakova, 2005), paving the road
for their potential use in the treatment of PD. The use of MSCs offers multiple
advantages over using other types of SCs in the treatment of PD. For instance, MSCs can
be readily harvested and cultured in vitro (Bianco et aI., 2001). Moreover, no ethical
limitations are associated with the use of autologous MSCs as opposed to hESCs or
allogeneic NSCs. MSCs are poorly immunogenic due to the lack of major
histocompatibility

complex

(MHC)-II

expressIOn,

reducing

the

need

for

immunosuppressive therapy (Morandi et aI., 2008). In fact, MSCs may possess inherent
immunosuppressive activity, as shown by Zhang et ai. that MSCs inhibit mitogen
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stimulated T lymphocyte proliferation (Zhang et aI., 2008). Importantly, no tumor
formation or significant adverse side effects have been reported following the
implantation of MSCs into the brains of PD animal models (Trzaska and Rameshwar,
2007).

A number of in

V1VO

studies have shown the ability of MSCs to induce therapeutic

behavioral improvement in murine animal models of PD (Bouchez et aI., 2008; Li et aI.,
2001). Interestingly, human umbilical cord matrix-derived MSCs, transplanted into the
brains of non-immunosuppressed murine models of PD, showed significant functional
improvement with no tumor formation, confirming their immunomodulatory properties
and potential for use in non-autologous transplantation (Weiss et aI., 2006). Noteworthy,
reports have also indicated that grafted MSCs could migrate to the site of injury and
enhance the number of tyrosine hydroxylase--positive neurons in the brain (Jin et aI.,
2008; Sadan et aI., 2009). Interestingly, even systemically-administered MSCs have been
shown to promote behavioral recovery in a rat model of PD (Park et aI., 2008a). This
observation led to the conclusion that certain chemokines secreted from the damaged
brain tissues attract MSCs to the site of brain damage.

More recently, genetically-modified MSCs have been investigated as a more robust
therapeutic approach in the treatment of PD. For instance, intrastriatally transplanted
vascular endothelium growth factor-expressing human umbilical cord-derived MSCs
differentiated into dopaminergic neurons and ameliorated motor abnormalities in a rat
model of PD (Xiong et aI., 2011). Similarly, intrastriatal implantation of GDNFexpressing human bone marrow-derived MSCs in a rat model of PD resulted in the
sprouting of rejuvenated tyrosine hydroxylase--positive neurons around the graft and
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significant functional improvement in parkinsonian symptoms (Glavaski-loksimovic et
aI., 2010). In addition, another group reported that transplantation of brain-derived
neurotrophic factor-secreting MSCs into the SNpc of a murine model of PD resulted in
enhanced grafting and neuroprotection (Somoza et aI., 2010).

In addition to neurotrophic factors, the dopamine synthesizing enzyme, tyrosine
hydroxylase, has also been overexpressed in MSCs. When tyrosine hydoxulaseexpressing bone marrow-derived MSCs were induced to differentiate into NSCs and
injected into the brain lateral ventricle of parkinsonian rats, considerable behavioral
recovery was observed, indicating the ability of injected modified NSCs to migrate
through the cerebrospinal fluid brain barrier into the damaged SNpc (Zou et aI., 2010).
Consequently, the study also highlights the possibility of less invasive approaches such as
ventricular or even subarachnoid transplantation of SCs. Recently, a combination of
tyrosine hydroxylase-- and GDNF-expressing MSC preparations were shown to have
superior therapeutic effect than either alone when implanted into the striatum of a rat
model of PD (Shi et aI., 2011). This study suggests synergism between tyrosine
hydroxylase and GDNF in the treatment of PD. Similar synergy has been reported when
using both tyrosine hydroxylase-- and brain-derived neurotrophic factor-expressing
astrocytes in animal models of PD (Wang et aI., 2002). However, more conclusive
studies comparing the effectiveness of normal versus genetically-modified SCs are
needed.
The exact mechanism of the therapeutic effects of MSCs in neurodegenerative disorders
such as PD is still controversial. Some studies indicate that MSCs exert their beneficial
effect by expressing neurotrophic factors that exert neuroprotective effects on
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dopaminergic neurons (Pereira et aI., 2011). Consistent with that, MSCs exhibit a unique
genetic expression profile enriched in angiogenic and neurogenic genes (Secco et aI.,
2009). A number of reports have proposed that MSCs act by enhancing axonal growth of
the dopaminergic neurons (Sasaki et aI., 2009; Shen et aI., 2006). In addition, the antiinflammatory effect of MSCs by reducing microglial activation has been proposed as a
means for their immunomodulatory activity and thus, therapeutic effects in PD (Park et
aI., 2008a). Interestingly, when transplanted into the striatum of a rat animal model,
MSCs showed no differentiation into dopaminergic neurons (Blandini et aI., 2010). This
study also showed that whereas some of the grafted MSCs differentiated into glial-like
cells, the grafted cells still exerted anti-parkinsonian effect. Taken together, these results
indicate that MSCs do not necessarily act by replacing dopaminergic neurons but rather
by protecting the remaining dopaminergic neurons or by reversing degeneration.
Although, in vitro and in vivo animal studies have reported promising results with the use
of MSCs in the treatment of PD, preliminary human clinical trials have yielded
controversial results. A recent study evaluated the use of autologous bone marrow MSC
transplantation in the striatum of 7 patients (Venkataramana et aI., 2010). After an openlabel 12- to 36-month period of observation, only modest behavioral improvement was
observed. This might have originated from a placebo effect because the magnetic
resonance imaging scan did not show any differences in the brain pre- and postoperatively, indicating that the grafts may not have survived in the brain after the surgical
procedure. Fortunately, no adverse effects or tumor-like formations were detected during
the course of the study. This study indicates that more investigations are still needed
before MSCs could be clinically employed to treat patients with PD.
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lId. Neural stem cells
NSCs are multi potent SCs present in specific areas of the brain, including the
subventricular zone and the subgranular zone of the hippocampal dentate gyrus (Eriksson
et aI., 1998; Roy et aI., 2000). However, NSCs obtained from the ventral mesencephalon
are thought to differentiate more efficiently into dopaminergic neurons as compared to
those harvested from other parts of the brain (Jonsson et aI., 2009). Utilizing fetal or adult
NSCs is thought to be a promising approach in the treatment of neurodegenerative
disorders due to their potential for self-renewal and differentiation into the three cell
lineages of the nervous system, viz., neurons, astrocytes, and oligodendrocytes (Gu et aI.,
2009; Lie et aI., 2002). More importantly, NSCs are associated with lower tumorformation risks after transplantation as compared to ESCs (Morizane et aI., 2008). In
addition, the use of PD patient-derived NSCs paves the way for autologous
transplantation and minimizes the need for immunosuppressive therapy (Arias-Carrion
and Yuan, 2009). Of note, since embryonic NSCs are associated with serious ethical
concerns, efforts have focused on developing methods to promote differentiation of adult
NSCs into dopaminergic neurons that could be used in the treatment of PD (Trzaska and
Rameshwar, 2007).

In 1998, Studer et aI. first reported the generation of tyrosine hydroxylase--positive cells
from embryonic rat mesencephalic precursors that exerted functional motor improvement
when transplanted in a rat model of PD (Studer et aI., 1998). Several subsequent studies
have confirmed the potential therapeutic effects of NSCs in PD. The intrastriatally
transplanted neuroepithelial SCs derived from mouse embryonic neural tube has been
shown to differentiate into dopaminergic neurons and to promote functional recovery in
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6-0HDA-lesioned rats (Sun et aI., 2007). In addition to their ability to differentiate into
dopaminergic neurons, NSCs have been suggested to exhibit neuroprotective effects in
vivo (Yasuhara et aI., 2006). The study showed that supernatants from human NSC

cultures exhibited neuroprotective effects on embryonic rat ventral mesencephalon
dopaminergic neurons when exposed to 6-0HDA toxicity in vitro. Following
transplantation into the brains of animal models of PD, most implanted human NSCs
either remain undifferentiated as neural progenitors or differentiate into non-neuronal
glial cells (Bjugstad et aI., 2008). To overcome low dopaminergic yield of differentiating
NSCs, O'Keeffe et aI. overexpressed the transcription factor Pitx3 in rat embryonic NSCs
derived from the ventral mesencephalon and co-cultured them with developing rat ventral
mesencephalon tissue (O'Keeffe et aI., 2008). The experiment showed an enhancement in
the yield of A9 dopaminergic neurons in vitro and a marked functional recovery
following transplantation in 6-0HDA-lesioned rats, probably due to secretion of
neurotrophic factors by the developing ventral mesencephalon.

Recently, genetically-engineered rat NSCs that overexpress neurotrophin-3 were shown
to be superior to non-modified NSCs in terms of regenerating dopaminergic neurons and
inducing functional recovery when transplanted in a rat model of PD (Gu et aI., 2009).
The study also demonstrated that neurotrophin-3-expressing NSCs were able to migrate
towards the damaged areas of the brain. Similarly, GDNF-expressing NSCs were shown
to enhance the survival of grafted dopaminergic neurons in vivo (Ostenfeld et aI., 2002),
and neurturin-expressing NSCs to improve functional recovery in parkinsonian rats (Liu
et aI., 2007).
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However, the use of NSCs in cell replacement therapy of PD faces several practical and
technical impediments. For instance, NSCs tend to lose their potential to give rise to
dopaminergic phenotype following in vitro expansion and tend to differentiate primarily
into glial cells in vivo (Bjugstad et aI., 2008; Chung et aI., 2006). Although it is generally
accepted that the more differentiated SCs would exert better therapeutic effects as
compared to undifferentiated SCs when transplanted in the brains of PD animal models,
early senescence of mature dopaminergic neurons is still a significant issue that has to be
resolved (Wang et aI., 2008). In fact, when compared to murine NSCs, human NSCs have
shorter telomeres indicating earlier senescence liability (Ostenfeld et aI., 2000).
Moreover, the effectiveness of NSCs transplantation is controversial since they already
exist in the brains of PD patients. However, one could argue that they are not produced in
sufficient quantities in the affected areas to halt the progressive degeneration of neurons
in PD patients. Another argument is the inability of endogenous NSCs to migrate long
distances to reach the damaged brain areas. Future studies should propose strategies to
enhance the viability and efficiency of differentiation of NSCs into dopaminergic neurons
to make their use more practical in the treatment of PD.
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CHAPTER IV
DISCUSSION

The advent of iPSC technology, together with the improved purification and
differentiation procedures, have made the potential for the therapeutic use of SCs in the
treatment of neurodegenerative disorders such as PD more imminent than ever.
However, several issues need to be addressed before SC-based cell replacement therapy
can be a clinically feasible reality in the treatment of PD.

One major obstacle facing SC-based therapy is the senescence and/or loss of cell viability
of transplanted cells within few weeks following transplantation. This may be attributed
to several factors including hypoxia, apoptosis, immune rejection, deficiency of trophic
factors, or oxidative stress (Sonntag et aI., 2005). Although the exact cause of early loss
of cell viability among transplanted neurons is not well understood, a few reports have
suggested the addition of exogenous factors to promote the survival of dopaminergic
neurons. For instance, Sanchez-Pernaute et aI. reported that exposure of primate SCs to
FGF2, FGF20 and Wnt5a (a signaling protein that regulates cell fate and patterning) at
the final stages of in vitro differentiation process enhanced their survival and thus
resulted in improved functional recovery in a rat model of PD (Sanchez-Pernaute et aI.,
2008). To overcome low survival of transplanted cell, further investigations are needed to
determine the proper developmental stage of SC differentiation for transplantation,
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identify the exact mechanism of early graft cell death, and propose methods to improve
their survival in host tissues.

The induction of an immunological reaction against the graft could be one reason for the
failure of SC therapy (Bradley et aI., 2002; Drukker et aI., 2002). It is therefore, useful to
reduce immunological responses exerted by host tissues towards grafts by using
autologous transplantation. Immune rejection may also arise from the presence of animal
products during the manipulation of SCs or from allogeneic transplantation (PreynatSeauve et aI., 2009), indicating the necessity for animal product-free transplants. In order
to reduce allogeneic transplantation-induced rejection in clinical therapy, blood group
compatible transplants should be used. Any induced trauma during the surgical
implantation of SCs could also trigger an inflammatory response that may amplify MHC
expression of both transplanted and recipient tissue cells (McLaren et aI., 2001). When
needed, the use of immunosuppressive therapy during and after surgery must be applied
to reduce immune rejection and the patients must be closely monitored for compromised
immunity-triggered complications.

Protocols and instruments used for the preparation of SC implants should be improved in
order to guarantee purity (dopaminergic neurons and/or precursors) and safety of the SC
preparations to avoid potential undesirable adverse effects. Traditionally, mouse
embryonic fibroblasts have been used as a supportive feeder layer for human pluripotent
SCs as they offer a cellular substrate for SC adhesion, mimicking physiological milieu,
and release suitable nutrients into the medium to support self-renewal and survival of SCs
(Abraham et aI., 2010). Animal-derived contamination of grafted cells may lead to the
transmission of animal retroviruses and other pathogens to patients. Therefore, several
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studies have proposed several protocols to avoid the use of animal products during the
culture and differentiation of SCs (Abraham et aI., 2010; Lei et aI., 2007; Mallon et aI.,
2006; Unger et aI., 2008). Furthermore, SC-derived implants, considered as a therapeutic
product, must be prepared aseptically during manipulation and transplantation, to
eliminate the risk of infection. Even the presence of fibroblasts in a human umbilical
cord-derived MSC graft yielded undesirable results in animal models of PD (Pereira et
aI., 2011). This study showed that the presence of fibroblasts reversed the therapeutic
effects of MSCs and promoted neuronal degeneration of the basal ganglia. These authors
proposed that the presence or absence of fibroblasts in implants could be the reason for
contradictory results achieved by different groups assessing the efficiency of MSCs in the
treatment of PD.

Transplantation of pluripotent SCs and dopaminergic progenitors is accompanied by the
risk of tumorigenicity. Hence, depleting residual undifferentiated pluripotent and/or
progenitor populations (figure 7) is crucial to prevent the potential for tumor formation
(Allan et aI., 2010). However, it has been shown that using FACS to enrich mouse
dopaminergic neurons could result in diminished neuronal survival profile (Hedlund et
aI., 2008). Although it is generally accepted that the longer SCs are left to differentiate in
vitro, the lower the potential for teratoma formation following transplantation (Preynat-

Seauve et aI., 2009), differentiated cells are less stable and more difficult to manipulate.
Noteworthy, recent investigations reveal a significant level of overlap in gene expression
between hESC- and hiPSC-derived cells and cancer cells, suggesting that pluripotent SCderived cells may possess oncogenic potential even after differentiation (Ghosh et aI.,
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2011).Therefore, carrying out studies to fully understand tumor-formation pathways and
identify compounds that can inhibit these pathways would prove valuable.

sc

DA precursor

DAneuron

Figure 7. Elimination of all pluripotent <;tem cells (follo\-\lI1g differentiation) through the use of
fluorescence-activated cell sorting or by inducing . elective ap()pt(l~is must be carried out before
transplantation in PO patients to avoid the formation of teratoma~ . (SC: stem cell. OA: dopaminergic)

As mentioned earlier, the brain microenvironment plays a major role in the pathology of
endogenous and transplanted neurons. The microenvironment that initially led to PDassociated neuronal death may also promote degeneration of the transplanted cells.
Recent investigations on patients with grafted fetal ventral mesencephalon showed that
transplanted cells were affected by the brain surrounding microenvironment. In fact,
pathological features typically seen in degenerating dopaminergic neurons in PD were
also observed in grafted neurons (Kordower et aI., 2008; Li et aI., 2008). While a
definitive understanding of the exact role of surrounding stroma in neurodegeneration is
still lacking, a study by Redmond et aI. suggests that the reciprocal relationship between
transplanted NSCs,

that express

neuroprotective factors,

and

the pathological

microenvironment, is responsible for the functional improvement observed in primate
models of PD. The authors implanted undifferentiated NSCs into the brains of MPTPtreated primates and found that while only a few of the transplanted NSCs differentiated
into tyrosine hydroxylase-positive dopaminergic neurons, the vast majority of the SCs
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became growth factor-secreting astrocytes in the vicinity of the developing dopaminergic
neurons (Redmond et aI., 2007). These observations led to the conclusion that astrocytes
secrete neurotrophic, angiogenic and anti-inflammatory factors that alter the toxic
microenvironment in the damaged areas of the brain, thereby improving the parkinsonian
symptoms. Consistent with these findings, NSCs have been shown to constitutively
secrete specific neurotrophic factors that promote regeneration following spinal cord
injury (Lu et aI., 2003). Thus, the field of SC therapy should focus not only on replacing
the dopaminergic neurons, but also on protecting the remaining endogenous neurons by
altering the surrounding brain microenvironment.
Transplant preparation should contain enough dopaminergic progenitors and/or midbrain
A9 dopaminergic neurons that would survive, communicate properly with the other
neuronal circuits in the brain, and induce marked therapeutic effect for at least several
months after surgery, to justify such an invasive SC-based therapy in the treatment of PD.
Maintaining the right dopamine physiological levels in the basal ganglia is crucial since
lower or higher concentrations will result in undesirable hypo- or hyper-kinetic
manifestations. The possibility that SCs derived from PD patients may generate
pathological neurons due to inherent genetic abnormalities (Park et aI., 2008b) poses
another major impediment for SC-based therapy. Furthermore, SC-derived preparations
are permanently placed in the brain making it difficult to reverse the therapy in case the
treatment resulted in serious adverse effects. The fact that other non-dopaminergic
neurons such as the noradrenergic neurons of the locus coeruleus and the serotonergic
neurons of the raphe nucleus could also degenerate particularly in the advanced stages of
PD, further complicates cell-based therapy (Ahlskog, 2007).
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Novel animal models and novel assessments of functional recovery should be designed to
better reflect the different stages of the disease and the degree of recovery after cell
replacement therapy. Typically, 6-0HDA treatment is thought to induce neuronal toxicity
on monoamine-secreting neurons of the brain creating a somewhat reliable murine model
of PD (Przedborski et ai., 1995; Ungerstedt, 1968). On the other hand, non-human
primate models of PD are typically induced by injecting MPTP (Eslamboli et ai., 2005;
Muramatsu et ai., 2009; Takagi et ai., 2005). However, these chemically-induced PD
models are not progressive in nature and are not associated with the formation of
proteinaceous Lewy bodies as observed in human PD, raising doubts about the reliability
of these models. Development of genetic and/or slowly progressive animal models of PD
will offer more robust and credible simulation of the disease that can be exploited to
further understand the pathophysiology of the disease and identify novel therapeutic
approaches (Litvan et ai., 2007a).

Several questions remain to be addressed regarding the conditions and mode of delivery
of SC-derived implants. For instance, how many cells should be transplanted? Is it better
to inject SC-derived cells in the SNpc or the striatum or both? The two main plausible
sites of injection are the SNpc and the corpus striatum. Intrastriatal implantation of SC
preparations was adopted mostly because this is where the physiological dopamine is
secreted. In addition, earlier fetal mesencephalic grafting studies in PD patients had
adopted the intrastriatal rather than the intranigral placement of grafts. However, some
studies have stated that intranigral injection resembles more closely the normal
physiological state and thus it is superior to intrastriatal placement, provided that the
resulting dopaminergic neurons would be able to extend axons to the striatum and
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integrate properly with adjacent tissues (Preynat-Seauve et al., 2009). The main factors
affecting the outcome of SC-based therapy in PD are shown in figure 8.
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There is still much work to do regarding the design of clinical studies in terms of patient
selection: whether these experiments should be carried out on early-, middle- or latestaged patients, and whether safety and/or efficacy are to be evaluated. Noteworthy, the
possibility that transplanted SC-derived cells may dedifferentiate or migrate to
unintended areas of the brain, which may affect patients' mental cognition, poses an
enormous ethical obstacle in warranting clinical trials. Therefore, SC-based therapy is
still largely an experimental approach with MSCs being the only type of SCs to have
been analyzed in a small-sized open-label clinical trial. Finally, a recent report goes
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beyond the aforementioned concerns and limitations to suggest that the functional
improvements observed in cell replacement therapy-treated PD patients are attributed to
the surgery and/or the psychological effects associated rather than to the transplanted SCderived preparations. In 2000, six PD patients enrolled in a Titan Pharmaceuticalsdesigned phase I clinical trial, known as Spheramine, in which cultured human retinal
epithelial cells were implanted into the brain. A year later, the patients showed a 48%
improvement in motor function that largely lasted for 4 years. Later on, investigators
found out that Spheramine was no more effective than placebo, suggesting that the brain
surgery rather than the transplanted dopamine-secreting cells was responsible for the
reported motor improvement and indicating a potential therapeutic role for sham brain
surgery in the treatment of PD (Katsnelson, 2011).

Consistent with that, the placebo effect plays a prominent role in the functional
improvements observed in treated PD patients through a reward-expectation mechanism
which apparently results in dopamine release into the striatum (de la Fuente-Fernandez
and Stoessl, 2002). In fact, the placebo group and the dopamine agonist (pergolide) treated group showed similar functional improvement (23% and 30% after 24 weeks
respectively) (Diamond et aI., 1985). Further, several articles reviewed by Shetty et al
reported a functional improvement following placebo treatment in PD patients, ranging
from -10 to -60% of that seen in the drug-treated group (Shetty et aI., 1999).
Interestingly, during a six-month study, 16% of PD subjects improved markedly on
placebo-treatment, exhibiting 50% improvement or scoring a change in at least two motor
items by

~

2, based on the UPDRS (Goetz et aI., 2000). On the other hand, it is

conceivable that the therapeutic efficacy of cell-based preparations in PD goes beyond
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mere psychological effect smce their use in clinical trials were accompanied with
improvements in

18F_dopa

uptake (an indicator of levo-dopa intake by dopaminergic

neurons), profuse dopaminergic neuron re-innervation, and formation of functional
synapses in the host striatum (Hagell and Brundin, 2001).

In summary, although SC-based cell replacement therapy is enticing in PD as it offers a
replacement for dead neurons and a neuroprotection for the remaining functional ones,
several obstacles hinder its clinical application in patients. Of all investigated
impediments early senescence and the potential tumorigenicity of transplanted cells pose
major challenges for the application of cell-based therapy. Moreover, the required good
manufacturing practice (GMP) standards during the preparation and transplantation of the
transplants in addition to the technical and practical issues associated with the application
of such a sophisticated approach in an extremely sensitive organ (the brain) pose major
challenges. Hence, it is obvious that SC-based therapy for PD is still at an early stage
and that more investigations are needed to resolve the associated safety, efficacy and
technical concerns.
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CHAPTER V
CONCLUSION

PD presents a major challenge because none of the existing therapies are capable of
halting and/or reversing the progressive neurodegeneration. Newer approaches involving
neurotrophic factors, gene therapy and SCs are advantageous and must be further
developed since they offer a modifying potential to PD pathophysiology, either by
replacing and/or protecting dopaminergic neurons. Among the newer approaches, only
SC-based therapies actually provide a replacement for lost dopaminergic neurons in PD.
It is encouraging that this relatively new field is advancing fast, achieving significant

results in animal models of PD, albeit with a few unresolved concerns. Among these
concerns, ethical issues, poor survivability of transplants and the inherent tumorigenicity
of pluripotent SCs hinder further advancement of the field. It is thus imperative that
intense investigations be carried out to circumvent tumorigenicity and prolong
survivability. Placebo-controlled double-blind clinical trials should then be initiated in
patients to establish the safety and efficacy of SC-based anti-PD therapies. Success of
SC-based preparations will have implications not only in PD but also in other
neurodegenerative diseases including Alzheimer's disease. Hence it is conceivable that
once the current impediments facing SC-based cell replacement therapy are resolved, it
will emerge as an efficacious treatment of choice in combating PD.
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